Gregory Adams

Gregory Adams has a diverse work experience in the biotech and pharmaceutical industry. Gregory is currently the Chief Scientific Officer at Elucida Oncology, a clinical stage company that focuses on developing targeted ultra-small C'-dot Drug Conjugates for cancer treatment. Previously, they held roles as the Chief Scientific Officer at Sesen Bio, where they guided the development of antibody-based fusion proteins for cancer treatment, and at Viventia Bio Inc., where they led the development of their product line and worked on their IPO.

Gregory also has experience in academia, working as an Adjunct Associate Professor and Director of Biological Research and Therapeutics at Fox Chase Cancer Center. Gregory was involved in fostering collaborations between researchers and medical professionals to develop new biologic agents for the detection and treatment of cancer. Gregory also held roles at Temple University School of Medicine as an Adjunct Associate Professor.

In addition, Gregory has served as a member of the Scientific Advisory Boards of Integral Molecular, Sevion Therapeutics, Mersana Therapeutics, and Symphogen. Gregory was also the CEO and Co-founder of RAbD Biotech LLC, a start-up focused on designing and producing biotherapeutics using knowledge of protein structure and in silico design methods.

Overall, Gregory Adams has a strong background in scientific and clinical research, as well as experience in commercialization and leadership roles in the biotech industry.

Gregory Adams completed their Bachelor of Arts degree in Biology from the University of California, Santa Cruz, in the period from 1977 to 1981. Gregory later pursued higher education and obtained a Ph.D. in Immunology from the University of California, Davis, between 1984 and 1991.